• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Lifestyle Changes Deserve a 3-Month Trial

News
Article

Clinicians sometimes give patients a choice of medication or lifestyle changes to control blood pressure (BP) or cholesterol levels.

Clinicians sometimes give patients a choice of medication or lifestyle changes to control blood pressure (BP) or cholesterol levels. When patients choose medication, they are asked to return in 4 to 8 weeks. However, when they choose to make lifestyle modifications, it's a good idea to wait 3 months to recheck BP or cholesterol levels. Most patients can adhere to a diet and exercise program for a month or two, but at 3 months, you'll have a better idea of whether they can maintain their new regimen.

-- 
Richard A. Honaker, MD Carrollton, Tex


 

More Practical Pointers >>

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Sydney Jennings
April 11th 2025
Article

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

Sydney Jennings
April 1st 2025
Article

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology

Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

Grace Halsey
March 31st 2025
Article

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Women's Heart Health News: 5 Studies from ACC.25 / image credit ©Hamza/stock.adobe.com

Women's Heart Health: 5 Studies from ACC.25

Hayden E. Klein
March 28th 2025
Article

The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.

© 2025 MJH Life Sciences

All rights reserved.